Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Diabetes

Journal Scan / Research · June 06, 2023

Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Individuals With Basal–Bolus Insulin-Treated Type 2 Diabetes

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
Lancet 2023 May 05;[EPub Ahead of Print], C Mathieu, B Ásbjörnsdóttir, HS Bajaj, W Lane, ALSA Matos, S Murthy, K Stachlewska, J Rosenstock

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading